Author/Editor		Takač, Iztok
Title		Raziskava Breast cancer international research group - BCIRG 005
Translated title		Study Breast cancer international research group - BCIRG 005
Type		članek
Source		In: Takač I, Arko D, editors. 30 let Centra za bolezni dojk v Mariboru. Zbornik predavanj Simpozij z mednarodno udeležbo; 2003 maj 23; Maribor. Maribor: Splošna bolnišnica Maribor,
Publication year		2003
Volume		str. 129-39
Language		slo
Abstract		With the aim of evaluating the efficacy of different treatment strategies with docetaxel, doxorubicin and cyclophosphamide in adjuvant treatment of operabile breast cancer patients, the international interactive Breast Cancer International Research Group (BCIRG) conducted the study BCIRG 005 (also registered as TAX GMA 301), entitled A multicenter phase III randomized trial comparing docetaxel in combination with doxorubicin and cyclophosphamide (TAC) versus doxorubicin and cyclophosphamide followed by docetaxel (AC-->T) as adjuvant treatment of operable breast cancer Her2neu negative patients with positive axillary lymph nodes. The primary objective of the study is to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide (TAC) to treatment with doxorubicin and cyclophosphamide followed by docetaxel (AC-->T). Recruitment of patients took place from March 2000 to January 2003. During that period of time, 3134 patients from 38 countries were included in the study, among them 32 from Slovenia. Definitive results of the study will be available in the year 2013, which is 10 years after termination of recruitment.
Descriptors		BREAST NEOPLASMS ANTINEOPLASTIC AGENTS CHEMOTHERAPY, ADJUVANT DOXORUBICIN CYCLOPHOSPHAMIDE TAMOXIFEN DISEASE-FREE SURVIVAL